Archive
1250 articles, sorted by publication time.
Healx advances an epigenetic and mTOR inhibition strategy into an early-stage trial for relapsed or refractory sarcoma; it is a clinical test for AI-driven drug discovery, but no human safety or efficacy data are yet available.
Studies in mice and postmortem human brains show that damaged mitochondria accumulate within neurites; although lysosomes arrive to clear them, failed degradation leaves behind a new pathological structure.
Studies of human brain tissue and mice with Dravet syndrome link DNA released by neurons, microglial inflammation, and recurrent seizures in a single pathway; inhibiting cGAS alleviated seizure phenotypes in mice, but key questions remain before this approach can reach clinical treatment.
Evaxion is using algorithms to identify T-cell epitopes and modify viral antigens in an effort to intercept cytomegalovirus at multiple stages of its life cycle. Mouse results support the design approach, but human trials and demonstrated protective efficacy remain a long way off.
The new system targets the analysis of low-concentration hormones and toxic substances, claiming up to a fivefold increase in sensitivity and longer tolerance of complex matrices. However, existing data come primarily from manufacturer testing, and clinical laboratories must still complete validation for each individual test.
From correcting DNA to rewriting RNA, several biotech companies are pushing alpha-1 antitrypsin deficiency to the forefront of genetic medicine; two programs have received authorization for clinical trials in the United States, but human evidence remains very limited.
A 343-patient trial following abdominoplasty showed that both doses improved pain over 48 hours, while the higher dose also reduced rescue opioid use; however, the efficacy findings came primarily from a single surgical model, and safety and comparative advantages still require confirmation in Phase 3 studies.
Google recruited nearly 14,000 people through Fitbit to test five conversational agents. Systems that actively asked follow-up questions outperformed a general chat mode in differential diagnosis, but the key findings were based on only a small number of participants who self-reported diagnoses received during medical visits and are not yet sufficient to replace physicians.
A mouse study found that TRF2 changes dynamically across different muscle stem cell states and maintains their gene regulatory network; after losing this protein, the cells may not necessarily die, but they may forget how to repair muscle.
A research team used structural prediction and protein engineering to modify AI-derived adenine base editors, increasing efficiency by up to 36-fold at some test sites and reducing bystander editing; however, the findings remain at the cellular and preclinical validation stage.
A mouse study reveals that the gut microbiota can regulate liver macrophages through bile acids, influencing whether nanomedicines are intercepted by the liver or reach tumors; the finding also introduces a previously overlooked variable into drug-delivery research.
A first-in-human trial used CRISPR to modify donor hematopoietic stem cells, aiming to protect the post-transplant blood system from anti-CD33 drug attacks; all 30 patients achieved engraftment on schedule, but efficacy, long-term safety, and accessibility still require larger studies.